# Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Canonical URL: https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care--f3b44a24
Ticker: MDGL
Company: Madrigal
Source: Madrigal
Published: 2026-02-24 13:00 EST
## Summary

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in...

## Article Body
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page . A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com .

Investor Contact Tina Ventura, IR@madrigalpharma.com

Media Contact Christopher Frates, media@madrigalpharma.com
## Recent Company News
- 2026-07-21 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-004ea5d8) — Source: Madrigal
- 2026-07-16 12:00 EST — [Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-ho-8492a4a5) — Source: Madrigal
- 2026-07-13 12:00 EST — [Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-f27ea704) — Source: Madrigal
- 2026-07-06 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-cb20d3fa) — Source: Madrigal
- 2026-06-22 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-bbbe1357) — Source: Madrigal
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)